Celgene dips out of deals ahead of mega-merger
Celgene dips out of deals ahead of mega-merger
Pfizer Inks Real-World Oncology Data Collaboration With Concerto HealthAI
Pfizer Inks Real-World Oncology Data Collaboration With Concerto HealthAI
New Tools to the 4 Pillars of Cancer Treatment: Biomarker Testing and Chronic Cancers
New Tools to the 4 Pillars of Cancer Treatment: Biomarker Testing and Chronic Cancers
Top 10 Immuno-Oncology Startups
Top 10 Immuno-Oncology Startups
Lilly suspends Lartruvo promotion after Phase 3 failure
Κάντε like στη σελίδα μας στο facebook για να μαθαίνετε πρώτοι όλα τα νέα!! Dive Brief: Eli Lilly’s Lartruvo failed a Phase 3 study in advanced or metastatic soft … Continue Reading Lilly suspends Lartruvo promotion after Phase 3 failure
Νέα θεραπεία για νεφροκυτταρικό καρκίνωμα
Νέα θεραπεία για νεφροκυτταρικό καρκίνωμα
The 20 Hottest Pipeline Drugs to Watch in 2019
The 20 Hottest Pipeline Drugs to Watch in 2019
Roche’s Tecentriq gets first-line lung cancer approval
Roche’s Tecentriq gets first-line lung cancer approval
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
Nektar Therapeutics Presents New Clinical and Preclinical Data for its Immuno-Oncology Pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nektar Therapeutics Presents New Clinical and Preclinical Data for its Immuno-Oncology Pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Ready to Roll! Ten Q3 Biotech Earnings Reports to Watch Next Week
Ready to Roll! Ten Q3 Biotech Earnings Reports to Watch Next Week
Keytruda growth fuels Merck investment
Keytruda growth fuels Merck investment
Science behind Nobel winners spawned one of the biggest marketing duels in pharma history
Science behind Nobel winners spawned one of the biggest marketing duels in pharma history
A timeline of key moments in the development of checkpoint inhibitors
A timeline of key moments in the development of checkpoint inhibitors
H Bristol-Myers επενδύει 12 εκατ. στην Compugen για κλινική έρευνα
H Bristol-Myers επενδύει 12 εκατ. στην Compugen για κλινική έρευνα
Tecentriq sets the bar in small-cell lung cancer
Tecentriq sets the bar in small-cell lung cancer
